GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: GSK 257049
Biological: Tritanrix™ HepB/Hib
Biological: Rouvax™
Biological: Polio Sabin™
Biological: Stamaril™

First Posted Date: 2007-02-16

Last Posted Date: 2018-08-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 511

Registration Number: NCT00436007

Locations: 🇹🇿
GSK Investigational Site, Dar-es-Salaam, Tanzania

A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701

Completed

Conditions: HIV Infection

First Posted Date: 2007-02-16

Last Posted Date: 2008-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 35

Registration Number: NCT00435838

Locations: 🇨🇭
GSK Investigational Site, La Chaux-de-Fonds, Switzerland

Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

Phase 1

Completed

Conditions: Healthy Subjects
Depressive Disorder and Anxiety Disorders

Interventions: Drug: GSK163090

First Posted Date: 2007-02-15

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 13

Registration Number: NCT00435695

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Phase 4

Completed

Conditions: Rhinitis, Allergic, Seasonal

First Posted Date: 2007-02-15

Last Posted Date: 2018-03-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1000

Registration Number: NCT00435461

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Phase 1

Completed

Conditions: Infections, Cytomegalovirus

Interventions: Biological: GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A

First Posted Date: 2007-02-15

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT00435396

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: atorvastatin
Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin

First Posted Date: 2007-02-14

Last Posted Date: 2017-02-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 245

Registration Number: NCT00435045

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

Phase 2

Completed

Conditions: AIDS
HIV Infections

Interventions: Biological: HIV vaccine 732461

First Posted Date: 2007-02-13

Last Posted Date: 2019-10-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 180

Registration Number: NCT00434512

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Phase 2

Completed

Conditions: Herpes Zoster

Interventions: Biological: Herpes Zoster vaccine GSK1437173A Modified
Biological: Herpes Zoster vaccine GSK1437173A Low Dose
Biological: Herpes Zoster vaccine GSK1437173A High Dose
Biological: Herpes Zoster vaccine GSK1437173A Medium Dose
Biological: Placebo